Becton Dickinson CEO on Earnings, Waters Deal

Becton Dickinson reported strong quarterly earnings, driven by robust demand in diagnostics and medical technology, according to CEO Tom Polen during a February 2026 interview. The company completed its merger with Waters Corporation, expanding its life sciences and analytical instruments portfolio to strengthen research and clinical capabilities. Polen highlighted cost synergies from the Waters deal, expecting $300 million in annual savings by 2027 while accelerating innovation in biopharma and diagnostics. BD’s 2026 outlook remains optimistic, with projected revenue growth of 5-7%, fueled by the merged entity’s broader product offerings and global market reach. The CEO emphasized long-term investments in R&D, particularly in precision diagnostics and automation, to sustain competitive advantage amid evolving healthcare demands.